Who is sponsoring NCT05114239?

NCT05114239 is sponsored by Keith G. LeBlanc, Jr, MD.

What condition does NCT05114239 study?

NCT05114239 studies Wound Heal.

What drugs are being tested in NCT05114239?

Interventions: Timolol 0.25% Ophthalmic Solution, Standard Wound Care.

What is the status of NCT05114239?

NCT05114239 is currently UNKNOWN.

Last reviewed 2021-10-29 · How we verify

Topical Timolol: a Comparison of Surgical Outcomes

NCT05114239 Phase 2 UNKNOWN

The use of topical beta-blockers, such as 0.25% timolol, in promoting wound healing is currently emerging in the literature. The investigators will enroll 30 participants in a split scar study who have their skin cancer surgically removed resulting in a linear wound equal to or longer than 4cm. The objective of this randomized study is to determine the safety and efficacy of 0.25% timolol in promoting wound healing in wound closed primarily greater than or equal to 1.5 cm.

Details

Lead sponsor	Keith G. LeBlanc, Jr, MD
Phase	Phase 2
Status	UNKNOWN
Enrolment	30
Start date	2021-04-07
Completion	2022-12

Conditions

Wound Heal

Interventions

Timolol 0.25% Ophthalmic Solution
Standard Wound Care

Primary outcomes

Observed cosmetic difference of scar in treatment side versus control: Yes or no — 1 month after suture removal
Photo review of objective cosmetic difference by blinded physician
Observed cosmetic difference of scar in treatment side versus control: Yes or no — 3 months after suture removal
Photo review of objective cosmetic difference by blinded physician

Countries

United States